NX 1207 is promising for the treatment of benign prostatic hyperplasia

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1617, 2007-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia

By Shore Neal  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 2, 2010-02 ,pp. : 305-310

Informa Healthcare

Access to resources Recommend Favorite

Cetrorelix is promising for the treatment of benign prostatic hyperplasia

By  

Inpharma, Vol. 1, Iss. 1639, 2008-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Treatment options for benign prostatic hyperplasia

By Thurlow R.J.  

Expert Opinion on Emerging Drugs, Vol. 3, Iss. 1, 1998-06 ,pp. : 225-246

Informa Healthcare

Access to resources Recommend Favorite

Dutasteride for the treatment of benign prostatic hyperplasia

By Wu Christopher   Kapoor Anil  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 10, 2013-07 ,pp. : 1399-1408

Informa Healthcare

Access to resources Recommend Favorite

Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease

By Santillo Vincent M.   Lowe Franklin C.  

Drugs & Aging, Vol. 23, Iss. 10, 2006-01 ,pp. : 795-805

Adis International

Access to resources Recommend Favorite